A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
NCT07288567
This study is recruiting at 13 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 13 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Advanced Research Center Inc. · Anaheim, CA
- Inland Psychiatric Medical Group. · Chino, CA
- Proscience Research Group · Culver City, CA
- UCSF Neurosciences Clinical Research Unit (NCRU) · San Francisco, CA
Florida · 1
- Apg Research, Llc · Orlando, FL
Georgia · 3
- Atlanta Center for Medical Research · Atlanta, GA
- Salveo Integrative Health - Lawrenceville · Lawrenceville, GA
- Denali Health Atlanta, LLC · Stone Mountain, GA
Illinois · 1
- EmVenio Research Center - Prime Healthcare · Chicago, IL
Massachusetts · 1
- Boston Children's Hospital · Boston, MA
Ohio · 1
- University of Cincinnati Dept of Psychiatry and Behavioral Neuroscience · Cincinnati, OH
Texas · 2
- VAST Clinical Research · Garland, TX
- Memorial Hermann · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.